The 12th Invest in ME Research Conference June, 2017, Part 2
MEMum presents the second article in a series of three about the recent 12th Invest In ME International Conference (IIMEC12) in London.
Discuss the article on the Forums.

Harking the Cytokines Interleukin 17A

Discussion in 'Other Health News and Research' started by Ecoclimber, Apr 1, 2015.

  1. Ecoclimber

    Ecoclimber Senior Member

    Messages:
    988
    Likes:
    2,424
    Avonex (interferon beta-1a) is made from human proteins. Interferons help the body fight viral infections.Premission to repost by Prof. Gavin Giovannoni

    There are some in the ME/CFS medical field that believe ME/CFS is 'MS Light' or 'Atypical MS'. Dr. Hornig alluded to this fact recently. The reason I post these articles is the fact that research in one area may spill over into another area of research or the fact that researchers reviewing a site may look at the research in another disease category that could be related to theirs and it might raise their interest level.

    Harking the cytokines

    Balasa R, Maier S, Voidazan S, Hutanu A, Bajko Z, Motataianu A.
    An Intricate Mechanism of Action of Avonex in Relapsing Remitting Multiple Sclerosis Patients: Variation of Serum Titre of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-β.CNS Neurol Disord Drug Targets. 2015 Mar. [Epub ahead of print]

    INTRODUCTION:
    The immunopathogenesis of multiple sclerosis (MS) is a main field of research, together with the mechanism of action of most immune therapies in this disease, such as interferon beta. Interleukin (IL)-17 is considered to play a central part in the initial immune cascade in MS, though there are numerous interactions between other cytokines that might explain the heterogeneity of disease evolution and treatment response.

    MATERIAL AND METHODS:
    We tested the serum levels of IL-17A, IL-10 and transforming growth factor (TGF-β) using the enzyme-linked immunosorbent assay method in three small groups of relapsing-remitting MS patients: 10 being naïve without treatment, 10 patients receiving Avonex treatment early in the MS evolution (≤ one year from the MS onset) and 12 MS patients who received Avonex later in the disease evolution. The values were compared with those obtained from 32 healthy subjects using statistical analysis.

    RESULTS:
    In the naïve multiple sclerosis group: IL-17A values were statistically higher than among healthy subjects; IL-17A inversely correlated with MS duration; serum IL-17A negatively correlated with TGF-β. A direct correlation was found between the serum titre of IL-17A and IL-10 in the early treated multiple sclerosis group; the titre of IL-17A was significantly reduced compared with that from the late treated multiple sclerosis group.

    CONCLUSIONS: The role in MS pathology of IL-17A, IL-10 and TGF-β is only partially elucidated. IL-17 plays an important role in the inflammatory phase of relapsing-remitting MS and is diminished by Avonex (interferon beta-1a). Avonex (interferon beta-1a) drug is made from human proteins. Interferons help the body fight viral infections mainly if this disease modifying treatment is administered early in the evolution of MS.

    IL-17A MS.jpg


    IL-17 is considered to be a pro-inflammatory T cell growth factor and blocking it is a thought to be a good thing. IL-10 and transforming growth factor are thought to be ant-inflammatory actors but are also pro-B cell factors. IL-17 dropped with treatment and IL-17 levels correlated with IL-10 levels. Maybe not quite what was envisioned.
     
    Last edited: Apr 1, 2015
    alex3619 likes this.
  2. natasa778

    natasa778 Senior Member

    Messages:
    1,773
    Likes:
    2,456
    Isn't that the one that Lipkin et al. found dropped from high to low (lower than controls? ) after 3 years of ME? I so, assuming both studies are correct and can be replicated, this could be pointing towards a key difference in pathology of ME versus MS...
     

See more popular forum discussions.

Share This Page